Marksans Pharma Ltd
Marksans Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #68 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 4 strong
The short version
Management projects 15%-20% revenue growth for FY27, with some participants considering this conservative, suggesting 20%-25% could be achievable. Management is confident of 15%-20% revenue growth for FY27, with aspirations from some investors for 20%-25% growth as the new normal. - They aim to double revenue from INR3,000 crores to INR6,000 crores within the next five years. - EBITDA margins are expected in the 20%-21% range for FY27, with current margins around 25% in Q1 seen as influenced by volatility. - Profit after tax grew strongly by 173.9% YoY in Q1 FY27, reflecting operating leverage and improved margins. - Growth is expected to be broad-based across geographies, with Europe and U.S.
From Marksans Pharma Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Management projects 15%-20% revenue growth for FY27, with some participants considering this conservative, suggesting 20%-25% could be achievable.
- The company aims to double its revenue from INR3,000 crores within the next five years, indicating a strong growth trajectory.
- In the U.S., the immediate goal is to reach $300 million in revenue, with a longer-term outlook towards $400 million in about five years.
- Europe is targeted as a significant growth area with plans to expand into multiple countries through acquisitions, expecting about INR1,000 crores revenue from Europe within five years.
- Organic growth is strong, especially in UK and Europe, with 50%+ year-on-year growth reported recently in the UK market.
2 more points from Marksans Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Marksans Pharma is exploring manufacturing capacity expansion with plans for potentially another unit in India within 1-2 years to meet 3-5 year growth goals, but no concrete plans finalized yet.
- The company is actively seeking inorganic growth opportunities and acquisitions, especially in Europe, to expand its footprint. They have done smaller deals in Europe (Netherlands, Germany) but plan more acquisitions as part of growth strategy.
- Management is conservative with cash usage, focusing on safe, high-return investments primarily in acquisitions rather than financial instruments.
2 more points from Marksans Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book remains strong, indicating healthy demand.
- Growth contributions are expected from multiple geographies, including the U.S., Europe, Australia, and other subsidiaries.
- The company anticipates continuing growth momentum across all markets in the current financial year.
2 more points from Marksans Pharma Ltd's call on order book
Create a free account to keep reading this call
Marksans Pharma Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹856 Cr, net profit ₹149 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Marksans Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Marksans Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Marksans Pharma Ltd Q1 FY27 results?
Management projects 15%-20% revenue growth for FY27, with some participants considering this conservative, suggesting 20%-25% could be achievable. Management is confident of 15%-20% revenue growth for FY27, with aspirations from some investors for 20%-25% growth as the new normal. - They aim to double revenue from INR3,000 crores to INR6,000 crores within the next five years. - EBITDA margins are expected in the 20%-21% range for FY27, with current margins around 25% in Q1 seen as influenced by volatility. - Profit after tax grew strongly by 173.9% YoY in Q1 FY27, reflecting operating leverage and improved margins. - Growth is expected to be broad-based across geographies, with Europe and U.S.
What is Marksans Pharma Ltd share price analysis?
Marksans Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 28.2 with a market cap of ₹14,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Marksans Pharma Ltd planning capital expenditure?
Marksans Pharma is exploring manufacturing capacity expansion with plans for potentially another unit in India within 1-2 years to meet 3-5 year growth goals, but no concrete plans finalized yet.
Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.